Exploring Novel Endpoints for Clinical Trials in Kidney Disease: Challenges and Opportunities
Author:
Publisher
Elsevier BV
Subject
Nephrology
Reference6 articles.
1. The number, quality, and coverage of randomized controlled trials in nephrology;Strippoli;J Am Soc Nephrol,2004
2. Baricitinib versus placebo or adalimumab in rheumatoid arthritis;Taylor;N Engl J Med,2017
3. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease;Perrone;Kidney Int Rep,2017
4. A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease;Perrone;Kidney Int Rep,2017
5. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration;Levey;Am J Kidney Dis,2014
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges;Advances in Kidney Disease and Health;2023-05
2. A Rare Kidney Disease To Cure Them All? Towards Mechanism-Based Therapies for Proteinopathies;Trends in Molecular Medicine;2021-04
3. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis;Kidney International;2019-08
4. Overview of Clinical Trials in Glomerulonephritis;SN Comprehensive Clinical Medicine;2019-05-20
5. Early intraoperative iron-binding proteins are associated with acute kidney injury after cardiac surgery;The Journal of Thoracic and Cardiovascular Surgery;2019-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3